Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Crisil - Panacea Biotec Ltd - Independent Equity Research Report

Posted On: 2011-12-14 22:00:23

Panacea Biotec Ltd (Panacea) has so far witnessed strong business momentum in both combination vaccines and formulations. While demand continues to gain traction, Panacea's growth will likely hit a roadblock as WHO (World Health Organisation) has de-listed its combination vaccines, including the high-margin EasyFive, from the pre-qualified list of vaccines. We have lowered our FY12 estimates to account for the loss in business. However, we maintain our fundamental grade of 3/5 as we believe that the problem is likely to be a short term one and the long-term business prospects look optimistic. Growth momentum in combination vaccines stalled in the near term.

Combination vaccines had been witnessing strong traction in demand, apparent from EasyFive's ~220% y-o-y revenue growth in FY11. WHO has recently delisted the product because of quality management issues. Consequently, we expect growth to get stalled as UNICEF is the largest customer. However, management is expecting to fix the issue in 3-4 months. We expect the supplies to resume by Q1FY13 and remain optimistic on the long-term growth prospects of combination vaccines.

Expect gradual de-growth in polio vaccine sales

Polio vaccine sales declined by ~17% y-o-y in FY11 largely due to: 1) decline in procurement by UNICEF because of increase in polio eradication globally, and 2) Indian government now procuring vaccines on need basis only. However, we view limited near-term risk to demand for polio vaccines given the significant number of cases still recorded globally. Going ahead, we expect sales to de-grow, but on a more gradual curve.

New products and geographic expansion to benefit formulations

Formulation sales grew ~24% y-o-y in FY11, largely driven by strong traction in its existing products and entries into new markets. Exports grew by ~110% driven by strong demand for Tacrolimus and Cyclosporine in Latin America. Going ahead, we believe that catalysts such as expected approval in regulated markets and launch of new products will continue to crank the growth engine.

Revenue growth and profitability curve to cave-in in FY12

We expect FY12 revenue to decline ~25% y-o-y to ~Rs 8,650 mn and EBITDA margin to contract by 1,440 bps to ~8% on loss of EasyFive sales to UNICEF and higher raw material costs driven by unfavourable forex movement. We expect revenue and margins to improve to ~Rs 11,934 mn and 19.0% in FY13.

Valuations the current price has 'upside'

Based on our new estimates, we arrive at a fair value of Rs 100 per share. We propose a valuation grade of 4/5, indicating that the market price has upside from the current levels.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Radico Khaitan - 3QFY2016 Result Update - Angel Broking
Eicher Motors - 4QFY2016 Result Update - Angel Broking
Goodyear India 4QFY2016 Results: Angel Broking
Amara Raja Batteries - 3QFY2016 Result Update - Angel Broking
Automobile Sector Monthly Update - LCV recovery accelerates; PVs under pressure - January 2016 - Angel Broking
Indoco Remedies - 3QFY2016 Result Update - Angel Broking
Larsen & Toubro - 3QFY2016 Result Update - Angel Broking
Alembic Pharma - 3QFY2016 Result Update - Angel Broking
Yes Bank - 3QFY2016 Result Update - Angel Broking
Maruti Suzuki - 3QFY2016 Result Update - Angel Broking
Power Grid Corporation of India - 3QFY2016 Result Update - Angel Broking
UltraTech Cement - 3QFY2016 Result Update - Angel Broking
Hindustan Media Ventures - 3QFY2016 Result Update - Angel Broking
Hindustan Zinc - 3QFY2016 Result Update - Angel Broking
Linc Pen & Plastics Ltd (LPPL) 3QFY2016 Results: Angel Broking
Sadbhav Engineering Ltd 3QFY2016 Results: Angel Broking
Buy Neuland Labs: AnandRathi Institutional Research
Radico Khaitan 3QFY2016 Results - Earnings outperform, top-line flat YoY - Angel Broking
Dishman Pharma 3QFY2016 Results: Angel Broking
Lupin 3QFY2016 Results: Angel Broking
Eicher Motors 4QFY2016 Results: Angel Broking
Buy Escorts: AnandRathi Institutional Research
Cadila Healthcare 3QFY2016 Results: Angel Broking
Tata Steel 3QFY2016 Results - EBITDA disappoints led by poor performance in Europe - Angel Broking
Views on Visaka Industries 3QFY2016 Result: Angel Broking
Views on Sanofi India 4QCY2015 Results: Angel Broking
Views on Bajaj Auto 3QFY2016 Results: Angel Broking
BUY Aegis Logistics: AnandRathi Institutional Research
BUY Century Plyboards: AnandRathi Institutional Research
Views on Transport Corporation of India Ltd 3QFY2016 Result: Angel Broking
Views on Tech Mahindra 3QFY2016 Results: Angel Broking
BUY Indoco Remedies - AnandRathi Institutional Research
Buy IRB Infrastructure : AnandRathi Institutional Research
Buy Granules India: AnandRathi Institutional Research
Views on Blue Star 3QFY2016 Results: Angel Broking
Views on Larsen & Toubro 3QFY2016 Results: Angel Broking
Views on United Phosphorus Ltd 3QFY2016 Results: Angel Broking
Views on Indoco Remedies 3QFY2016 Results: Angel Broking
Views on Yes Bank 3QFY2016 Results: Angel Broking
Views on TVS Motors Company 3QFY2016 Results: Angel Broking
Views on Maruti Suzuki India Ltd 3QFY2016 Results: Angel Broking
Views on ICICI Bank 3QFY2016 Results : Angel Broking
Views on Gujarat Pipavav Port 3QFY2016 Results: Angel Broking
Views on Jyothy Laboratories 3QFY2016 Result: Angel Broking
Views on HDFC Ltd 3QFY2016 Result: Angel Broking
BUY Unichem Labs: AnandRathi Institutional Research
Views on Power Grid Corporation (PGCIL) 3QFY2016 Result: Angel Broking
Views on Bharat Electronics Ltd. (BEL) 3QFY2016 Result: Angel Broking
Views on Kirloskar Oil Engines 3QFY2016 Result: Angel Broking
BUY Ashoka Buildcon: AnandRathi Institutional Research


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2014